30.3 Ambulatory Community-Acquired Pneumonia

Community-Acquired Pneumonia: Epidemiology & Microbial Etiology

Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchymal tissue (alveolar spaces and interstitium) acquired outside of a hospital, inpatient facility, or long-term nursing home. CAP affects over 5 million adults annually in the United States, representing the leading cause of infectious mortality, with approximately 80% of cases managed entirely in the ambulatory outpatient setting.

Typical Bacterial Pathogens

• Streptococcus pneumoniae (Pneumococcus): Encapsulated Gram-positive lancet-shaped diplococcus. Remains the most frequent bacterial pathogen across all age groups. Classically presents with sudden onset of a single shaking chill (rigor), high fever, pleuritic chest pain, and rust-colored (prune-juice) sputum, producing dense lobar consolidation with air bronchograms on imaging.
• Haemophilus influenzae: Pleomorphic Gram-negative coccobacillus. Highly prevalent in elderly patients, chronic cigarette smokers, and patients with pre-existing chronic obstructive pulmonary disease (COPD) or bronchiectasis.
• Moraxella catarrhalis: Gram-negative diplococcus. Common in older adults with chronic lung disease; produces beta-lactamase in >90% of isolates.
• Staphylococcus aureus: Gram-positive cocci in clusters (MSSA and MRSA). Characteristically complicates post-influenza viral infections, causing rapid cavitary necrosis, pneumatoceles, empyema, and high mortality.
• Klebsiella pneumoniae: Encapsulated Gram-negative bacillus. Classically associated with severe chronic alcoholism, diabetes, and malnutrition; presents with thick, gelatinous, blood-stained "currant jelly" sputum, upper lobe cavitation, and the "bulging fissure sign" on radiography.
• Pseudomonas aeruginosa: Aerobic Gram-negative rod. Encountered primarily in patients with structural lung disease (severe cystic fibrosis, bronchiectasis) or advanced COPD requiring frequent systemic corticosteroids and broad-spectrum antibiotics.

Atypical Bacterial Pathogens

"Atypical" organisms lack a rigid peptidoglycan cell wall or replicate intracellularly, rendering them intrinsically resistant to beta-lactam antibiotics (penicillins, cephalosporins) and invisible on standard sputum Gram stains.

• Mycoplasma pneumoniae:
  • Lacks a peptidoglycan cell wall; enclosed only by a sterol-containing lipid trilaminar membrane.
  • Highly prevalent in young adults, college students, and military recruits in close quarters.
  • Clinical Features: Classic "walking pneumonia" — insidious onset of persistent dry hacking cough, low-grade fever, headache, malaise, pharyngitis, and prominent fatigue. Pulmonary examination is often deceptively normal despite extensive patchy bilateral infiltrates on radiography ("radiograph looks worse than the patient").
  • Extrapulmonary Complications: Bullous myringitis (hemorrhagic or serous blebs on the tympanic membrane), erythema multiforme (target lesions), Stevens-Johnson syndrome, and cold agglutinin-mediated autoimmune hemolytic anemia (elevated IgM cold agglutinins directed against erythrocyte I-antigens causing complement fixation).
• Chlamydophila pneumoniae: Obligate intracellular bacterium. Insidious onset, producing pharyngitis, laryngitis, and hoarseness followed days to weeks later by mild subacute pneumonia.
• Legionella pneumophila:
  • Fastidious Gram-negative bacillus inhabiting aquatic environments, air-conditioning cooling towers, hotel plumbing systems, hot tubs, and decorative fountains. Transmitted via inhalation of aerosolized contaminated water droplets (no person-to-person transmission).
  • Clinical Features (Legionnaires' Disease): Severe pneumonia characterized by:
    • Very high spiking fevers (often >40.0°C / 104°F);
    • Relative bradycardia (Faget sign): Heart rate inappropriately low relative to the height of fever;
    • Prominent gastrointestinal symptoms: Early watery, non-bloody diarrhea, severe nausea, abdominal cramping;
    • Neurologic abnormalities: Marked confusion, lethargy, encephalopathy, headache;
    • Distinctive Laboratory Abnormalities: Severe hyponatremia (serum Na <130 mEq/L, mediated by SIADH and renal wasting), elevated serum hepatic transaminases (AST, ALT), hypophosphatemia, and microscopic hematuria.
  • Diagnostic Confirmation: Urinary Legionella antigen test (detects L. pneumophila serogroup 1, responsible for 80-90% of community cases; sensitivity 70-90%, specificity >99%); respiratory PCR.
  • Treatment: Highly responsive to macrolides (azithromycin) or respiratory fluoroquinolones (levofloxacin); completely unresponsive to all beta-lactams.

Viral Pathogens

Viruses account for 20% to 30% of ambulatory CAP cases, led by Influenza A and B, SARS-CoV-2, Respiratory Syncytial Virus (RSV), Parainfluenza, and Human Metapneumovirus.

---

Clinical Presentation & Bedside Signs of Consolidation

• Symptoms: Productive or dry cough, fever, chills, dyspnea, tachypnea, anorexia, fatigue, and pleuritic chest pain (sharp, localized pain exacerbated by deep inspiration or coughing, indicating inflammatory rub of the richly innervated parietal pleura).
• Atypical Presentation in Older Adults: Fever, chills, and cough are frequently absent. Elderly patients often present with acute cognitive decline, new delirium, lethargy, falls, anorexia, or worsening of baseline congestive heart failure.

Physical Examination Signs of Alveolar Consolidation

                  PHYSICAL EXAMINATION SIGNS OF ALVEOLAR CONSOLIDATION

      Palpation                    Percussion                   Auscultation
   ┌──────────────┐             ┌──────────────┐             ┌────────────────┐
   │  INCREASED   │             │   DULLNESS   │             │  • LATE INSP.  │
   │   TACTILE    │             │      TO      │             │    CRACKLES    │
   │   FREMITUS   │             │  PERCUSSION  │             │  • BRONCHIAL   │
   └──────────────┘             └──────────────┘             │    BREATH SOUNDS
   (Solid dense lung            (Fluid-filled lung           │  • EGOPHONY    │
    conducts vocal sound         replaces aerated            │  • PECTORILOQUY│
    vibrations better)           resonance)                  └────────────────┘

• Tactile Fremitus: Increased tactile fremitus over the consolidated lobe. Consolidated alveolar tissue transmits low-frequency vocal acoustic vibrations ("ninety-nine") to the chest wall far more efficiently than air-filled spongy parenchyma. (Contrasts with pleural effusion or pneumothorax, where fremitus is decreased).
• Percussion: Dullness to percussion over consolidated lung (replaces the resonant sound of healthy aerated lung).
• Auscultation:
  • Late Inspiratory Crackles (Rales): Explosive opening sounds of previously collapsed small alveoli and terminal bronchioles.
  • Bronchial Breath Sounds: Harsh, loud, high-pitched tubular breath sounds with a prolonged expiratory phase heard over the peripheral lung fields (where soft, quiet vesicular breath sounds normally reside).
  • Egophony ("E-to-A Sign"): Spoken vowel sound "E" auscultates as a high-pitched, nasal, bleating "A" through consolidated parenchyma due to acoustic filtering of higher frequencies.
  • Whispered Pectoriloquy: Whispered syllables ("ninety-nine" or "one-two-three") are heard distinctly and clearly through the stethoscope over the consolidated region.

---

Diagnostic Imaging: Standard PA & Lateral Radiography

The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) guidelines require radiographic confirmation of a pulmonary infiltrate to establish the diagnosis of community-acquired pneumonia and differentiate it from acute bronchitis.

Radiographic Features

• Lobar Consolidation: Homogeneous water-density opacity confined within anatomic lobar or segmental margins.
• Air Bronchograms: Branching, dark (radiolucent) tubular airways visualized against a background of dense white (opaque) alveolar consolidation. This pathognomonic finding confirms alveolar fluid filling while the conducting bronchi remain patent.
• Patchy Interstitial / Alveolar Infiltrates: Diffuse, ill-defined opacities, frequently multifocal or bilateral, characteristic of atypical and viral pneumonias.
• Complications: Radiography identifies parapneumonic pleural effusions, empyema, lung abscesses, and cavitary lesions.

Follow-Up Imaging Guidelines

• Clinically Improving Patients: Routine repeat chest radiography is NOT recommended for outpatients who have clinically recovered.
• Radiographic Resolution Lag: Radiographic clearance lags significantly behind clinical improvement; complete resolution of consolidation typically requires 4 to 8 weeks (and up to 12 weeks in older adults or smokers).
• Indications for Follow-Up CXR at 6 to 8 Weeks:
  1. Age > 50 years;
  2. Current or former tobacco smokers;
  3. Persistent, unresolving, or recurrent respiratory symptoms.
  • Clinical Rationale: To ensure complete radiographic resolution and exclude an underlying endobronchial malignancy (bronchogenic carcinoma) that presented initially as post-obstructive pneumonia.

---

Outpatient vs. Inpatient Triage: CURB-65 & PSI Scores

Determining the site of care (ambulatory outpatient vs. inpatient floor vs. ICU) is the most critical decision in CAP management.

The CURB-65 Decision Tool

Assigns 1 point for each of the following 5 criteria:

• C - Confusion: New mental disorientation to person, place, or time, or Abbreviated Mental Test score ≤8;
• U - Uremia: Blood Urea Nitrogen (BUN) > 19 mg/dL (> 7.0 mmol/L);
• R - Respiratory Rate: Tachypnea with RR ≥ 30 breaths/min;
• B - Blood Pressure: Hypotension with Systolic BP < 90 mmHg OR Diastolic BP ≤ 60 mmHg;
• 65 - Age: Patient age ≥ 65 years.

Clinical Variant (CRB-65): In outpatient clinics lacking immediate laboratory BUN access, CRB-65 (Confusion, RR ≥30, SBP <90 or DBP ≤60, Age ≥65) is utilized: Score 0 = outpatient; Score 1-2 = hospital evaluation; Score ≥3 = urgent hospitalization.

Pneumonia Severity Index (PSI / PORT Score)

• A comprehensive 20-variable risk prediction tool assessing age, nursing home residence, 5 comorbidities, 5 physical examination findings, and 7 lab/imaging parameters.
• Classes I and II (Score <70): Outpatient management (mortality <1%).
• Class III (Score 71-90): Outpatient vs. short observation stay.
• Classes IV and V (Score >90): Inpatient hospital admission.
• The ATS/IDSA guidelines recommend PSI over CURB-65 due to higher diagnostic sensitivity and lower unnecessary admission rates; however, CURB-65 is widely favored in outpatient family practice for its rapid bedside calculation.

---

ATS/IDSA 2019 Outpatient CAP Pharmacotherapy Guidelines

                  ATS/IDSA 2019 OUTPATIENT CAP PHARMACOTHERAPY

                    Radiographically Confirmed CAP (CURB-65: 0-1)
                                        │
            ┌───────────────────────────┴───────────────────────────┐
            ▼                                                       ▼
   HEALTHY HOST WITHOUT COMORBIDITIES                      HOST WITH COMORBIDITIES
   • No chronic heart, lung, liver, or renal disease       • Chronic COPD, asthma, CHF, CAD
   • No diabetes, alcoholism, or malignancy                • Chronic kidney disease, cirrhosis
   • No asplenia or immunosuppression                      • Diabetes mellitus, alcoholism, asplenia
   • No antibiotics in past 90 days                        • Active cancer, immunosuppressed host
            │                                              • Antibiotics in past 90 days
            ▼                                                       │
   FIRST-LINE:                                                      ▼
   • Oral Amoxicillin 1 g TID x 5d (preferred)             OPTION A: COMBINATION THERAPY (Preferred)
   ───────────────────────────────────────────             • Beta-Lactam Component:
   ALTERNATIVES:                                             - Amoxicillin-Clavulanate 875/125 mg BID
   • Oral Doxycycline 100 mg BID x 5d                         (or Augmentin XR 2,000/125 mg BID)
   • Oral Macrolide (Azithromycin 500mg d1,                  - Cefpodoxime 200 mg BID, or
     250mg d2-5) ONLY if local pneumococcal                  - Cefuroxime 500 mg BID
     macrolide resistance is <25%                          • PLUS Atypical Component:
     (UNCOMMON IN THE UNITED STATES)                         - Azithromycin 500mg d1, 250mg d2-5, OR
                                                             - Doxycycline 100 mg BID
                                                           ─────────────────────────────────────────
                                                           OPTION B: MONOTHERAPY
                                                           • Respiratory Fluoroquinolone:
                                                             - Levofloxacin 750 mg PO daily x 5d, OR
                                                             - Moxifloxacin 400 mg PO daily x 5d
                                                             *(NEVER USE CIPROFLOXACIN)*

1. Healthy Outpatients WITHOUT Comorbidities

• Definition: No chronic cardiopulmonary, renal, or hepatic disease; no diabetes mellitus, alcoholism, malignancy, asplenia, or immunosuppressive condition; and no systemic antimicrobial exposure within the past 90 days.
• First-Line Regimen: High-Dose Amoxicillin
  • Amoxicillin 1 g PO three times daily (TID) for 5 days (Strong recommendation).
  • Clinical Rationale: Streptococcus pneumoniae is the dominant pathogen. High-dose amoxicillin achieves high alveolar epithelial lining fluid concentrations that overcome intermediate penicillin resistance in pneumococci.
• Alternative Regimen: Doxycycline
  • Doxycycline 100 mg PO twice daily (BID) for 5 days (Conditional recommendation).
  • Clinical Rationale: Provides excellent coverage against S. pneumoniae, H. influenzae, and atypical organisms (Mycoplasma, Chlamydophila). Preferred choice for patients with severe penicillin hypersensitivity (anaphylaxis).
• Conditional Regimen: Macrolide Monotherapy
  • Azithromycin 500 mg PO on Day 1, then 250 mg PO daily on Days 2 through 5, OR Clarithromycin 500 mg PO BID for 5 days.
  • CRITICAL RESTRICTION: Macrolide monotherapy is recommended ONLY in areas where pneumococcal resistance to macrolides is documented to be < 25%!
  • Board Pearl: In the United States, pneumococcal macrolide resistance exceeds 40% to 50% in almost all communities (mediated by ermB ribosomal methylases and mefA efflux pumps). Consequently, azithromycin monotherapy is generally NOT recommended as empiric first-line monotherapy in the US!

2. Outpatients WITH Comorbidities

• Definition: Presence of chronic heart disease (CHF, CAD), chronic lung disease (COPD, asthma, bronchiectasis), chronic liver disease (cirrhosis), chronic renal disease, diabetes mellitus, alcoholism, active malignancy, functional or anatomic asplenia, immunosuppressive conditions or medications, or recent systemic antibiotic use within 90 days.
• Pathogen Profile: Expanded risk for Gram-negative bacilli (Enterobacteriaceae, H. influenzae, M. catarrhalis), beta-lactamase producers, and drug-resistant S. pneumoniae (DRSP).
• Option A: Combination Therapy (Beta-Lactam PLUS Atypical Coverage) - PREFERRED:
  • Beta-Lactam Component:
    • Amoxicillin-Clavulanate (Augmentin): 875/125 mg PO BID, OR high-dose Augmentin 2,000/125 mg PO extended-release BID;
    • OR Cephalosporins: Cefpodoxime 200 mg PO BID, OR Cefuroxime axetil 500 mg PO BID;
  • PLUS Atypical Component:
    • Macrolide: Azithromycin 500 mg Day 1, then 250 mg daily; OR
    • Doxycycline: 100 mg PO BID.
• Option B: Monotherapy with a Respiratory Fluoroquinolone:
  • Levofloxacin 750 mg PO once daily for 5 days; OR
  • Moxifloxacin 400 mg PO once daily for 5 days.
  • THE CIPROFLOXACIN TRAP: Ciprofloxacin is NOT a respiratory fluoroquinolone! Ciprofloxacin possesses notoriously poor in vitro and in vivo activity against Streptococcus pneumoniae and must NEVER be prescribed for community-acquired pneumonia!
  • Fluoroquinolone Safety Warnings: Because of FDA boxed warnings regarding disabling and potentially irreversible adverse reactions (tendon rupture/Achilles tendinitis, QT prolongation with torsades de pointes, aortic dissection/rupture, severe peripheral neuropathy, CNS excitation/seizures, dysglycemia/hypoglycemic coma), respiratory fluoroquinolones are reserved for patients with severe allergies to beta-lactams or who cannot tolerate combination regimens.

Duration of Antimicrobial Therapy & Clinical Stability

• Minimum Duration: Antimicrobial therapy must be continued for a minimum of 5 days.
• Criteria for Discontinuation: The patient must achieve clinical stability (defined as being afebrile [temperature <37.8°C / 100°F] for at least 48 to 72 hours, heart rate <100 bpm, respiratory rate <24 breaths/min, systolic BP ≥90 mmHg, and oxygen saturation ≥92% on ambient air) before stopping antibiotics.
• Routine extension of treatment to 7 to 14 days in uncomplicated ambulatory CAP provides no clinical advantage and significantly increases adverse drug events and antimicrobial resistance.

Pneumococcal Immunization Guidelines

• Indications: All adults aged ≥65 years, and adults aged 19 to 64 years with high-risk underlying medical conditions (diabetes, chronic lung/heart/liver/renal disease, alcoholism, cigarette smoking, asplenia, immunocompromise).
• Vaccine Regimens: A single dose of PCV20 (Prevnar 20) alone, OR a single dose of PCV15 (Vaxneuvance) followed by PPSV23 (Pneumovax 23) at least 1 year later (or ≥8 weeks later in immunocompromised patients).